In contrast, NCPA delivered about 50% of CD47/PD‐L1 antibodies to the tumor site, indicating an about 2.5‐fold increase in tumor accumulation, which may be ascribed to the mannose‐modified NCPA capable of targeting CD206, which was overexpressed in the lung carcinoma tissue (Figure 3C). Here, MRC1 is linked to lung carcinoma.